Maria Harris Rasmussen

1 Introduction Chemical instability of active pharmaceutical ingredients (APIs) is a major concern throughout drug development, from preclinical screening to regulatory approval and beyond. Degradation during manufacturing, storage, or use can reduce therapeutic efficacy, introduce toxic byproducts, and necessitate costly reformulation efforts or even withdrawal from development [1-3].